A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older (Farnesyl transferase Inhibition Global Human trials AML 301 [F.I.G.H.T. AML 301])

Trial Profile

A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older (Farnesyl transferase Inhibition Global Human trials AML 301 [F.I.G.H.T. AML 301])

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms FIGHT-AML-301
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Apr 2010 Actual number of patients (457) added as reported by ClinicalTrials.gov.
    • 19 Sep 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
    • 07 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top